Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat-CHOP or pralatrexate-COP versus CHOP in newly diagnosed peripheral T-cell lymphoma
2023-507803-76-00Phase 3Authorised
- Sponsor
- Acrotech Biopharma Inc
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of belinostat and pralatrexate in peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Acrotech Biopharma Inc. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
belinostatpralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2023-507803-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507803-76-00.